Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Gotlib, Jason, Berubé, Caroline, Growney, Joseph D., Chen, Ching-Cheng, George, Tracy I., Williams, Christopher, Kajiguchi, Tomohiro, Ruan, Jia, Lilleberg, Stan L., Durocher, Jeffrey A., Lichy, Jack H., Wang, Yanfeng, Cohen, Pamela S., Arber, Daniel A., Heinrich, Michael C., Neckers, Len, Galli, Stephen J., Gilliland, D. Gary, Coutré, Steven E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The American Society of Hematology 2005
Pynciau:
Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895309/
https://ncbi.nlm.nih.gov/pubmed/15972446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-04-1568
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg